David L Pompliano

US Patent:

55254799, Jun 11, 1996

Filed:

Feb 17, 1994

Appl. No.:

8/199778

Inventors:

Neville J. Anthony - Hatfield PA
David L. Pompliano - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 148
C12Q 100
A01N 3718

US Classification:

435 15

Abstract:

This invention is directed to a continuous fluorescence assay of Ras farnesyl:protein transferase. This assay can be used to screen for inhibitors of farnesyl:protein transferase. The assay may also be modified to screen for inhibitors of other protein transferases.

US Patent:

58916210, Apr 6, 1999

Filed:

Sep 24, 1997

Appl. No.:

8/936646

Inventors:

Renee M. Chabin - Neptune NJ
David W. Kuo - Princeton NJ
John F. O'Connell - Cranbury NJ
David L. Pompliano - Lawrenceville NJ
Kenny K. Wong - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 100
C12Q 137
C12Q 118
C12Q 148

US Classification:

435 4

Abstract:

An in vitro screening assay which identifies enzyme inhibitors and allows for the simultaneous assay of many enzymes. Enzyme, substrate, co-factor, etc. concentrations are optimized so that inhibitors of any one of the enzymes in the pathway are equally likely to be detected. Necessarily, the flux of substrate through each enzyme should be nearly the same during the assay, i. e. , each of the enzyme catalyzed steps must be equally rate-limiting. Preferably, optimal assay conditions are predicted by computer modeling. Further, the pathway conditions are optimized through variation of enzyme, starting substrate, co-substrate and co-factor concentrations. A positive response is initially detected as a change in the amount of the product generated at the end of the enzyme cascade as compared to a standard. A sample producing a positive result can be deconvoluted.

US Patent:

54749212, Dec 12, 1995

Filed:

Oct 15, 1993

Appl. No.:

8/138641

Inventors:

Kenneth S. Koblan - Chalfont PA
David L. Pompliano - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 916
C12N 920
C12N 1555
C07K 122

US Classification:

435196

Abstract:

The present invention is directed to an assay which is used to determine the inhibitory activity of a test compound against a particular phosphoinositide-specific phospholipase C enzyme, that enzyme being phospholipase C. gamma. The present invention is also directed to the preparation of phospholipase C. gamma. by recombinant expression in a bacterial cell and isolation of the expressed enzyme.